BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a
rapidly growing commercial-stage specialty pharmaceutical company
dedicated to patients living with chronic conditions, today
reported strong financial results for the second quarter ended June
30, 2019, as well as the following operational and performance
highlights:
Key Business Highlights
- Total company net revenue increased by 144% versus the prior
year period to a new all-time high of $29.7 million.
This growth was driven by BELBUCA® (buprenorphine buccal
film), CIII sales of $24.1 million, an increase of 147% versus the
prior year period, and the addition of Symproic® (naldemedine)
tablets 0.2 mg to the commercial portfolio.
- Total BELBUCA prescriptions of more than 80,000 for the quarter
was the highest ever for any three-month period. In addition,
prescription growth for BELBUCA reached an all-time year-over-year
record increase of 44,560 prescriptions, representing a 125%
increase year-over-year and a 23% increase versus the prior
quarter.
- Achieved a new all-time high of 6,579 unique BELBUCA
prescribers during the quarter.
- Delivered highest ever number of quarterly prescriptions for
Symproic achieving greater than 14% quarter-over-quarter growth and
40% growth versus prior year.
- Significantly strengthened financial position through debt
refinancing, dramatically lowering cost of capital and extending
maturity.
“The second quarter was highlighted by dramatic
accomplishments across our entire organization and has positioned
us to further build upon our commercial success,” stated Herm
Cukier, Chief Executive Officer of BDSI. “We have significant
momentum with our core products and have strengthened the company’s
financial position. Our excellent performance in the second
quarter is the fifth consecutive quarter of sustained and rapid
growth. I believe our future is very promising, and as we
raise our full-year BELBUCA and total company net sales
expectations for the second time this year, we have great
confidence in our growth trajectory into 2020 and
beyond.”
The company again increased its expectations for
full-year 2019 BELBUCA net sales to $90 - $93 million, from the
previous level of $83 - $88 million. The company also raised
its total 2019 net sales expectations to $101 - $105 million, from
the previous level of $92 – $100 million. Total net revenue
expectations include $7 - $9 million of forecasted Symproic net
sales, which is in line with the company’s previous
expectation.
With the strong performance achieved over the
last five consecutive quarters, coupled with a solid balance sheet
supporting the execution of the commercial growth plan, the company
is raising its long-term combined net sales expectations for
BELBUCA and Symproic to $425 - $500 million.
Second Quarter 2019 Financial
Results
Total Net Revenue. Total
net revenue for the second quarter ended June 30, 2019, was $29.7
million, an increase of 50%, compared to $19.8 million in the first
quarter of 2019, and an increase of 144%, compared to $12.2 million
in the second quarter of 2018.
Total Net Product Sales.
Total net product sales in the second quarter were $28.1 million,
an increase of 42%, compared to $19.8 million in the first quarter
of 2019 and an increase of 161% compared to $10.8 million in the
second quarter of 2018. This includes net product sales of
Symproic of $3.2 million in the initial quarter of
commercialization following the acquisition of the
product.
BELBUCA Net Sales. BELBUCA net
sales in the second quarter were $24.1 million, an increase of 29%,
compared to $18.7 million in the first quarter of 2019 and an
increase of 147%, compared to $9.7 million in the second quarter of
2018.
Total Operating Expenses.
Total operating expenses in the quarter ended June 30, 2019, were
$22.0 million, compared to $17.0 million in the first quarter of
2019 and $14.9 million in the second quarter of 2018.
GAAP Net Loss. GAAP
net loss for the quarter was $11.1 million, or ($0.13) per share,
compared to the loss of $3.8 million, or ($0.05) per share, for the
first quarter of 2019 and a GAAP net loss of $9.8 million, or
($0.16) per share, in the second quarter of 2018. The increase in
net loss is driven by the one-time debt refinancing costs of $11.9
million.
EBITDA. EBITDA in the
second quarter of 2019 was $4.8 million or 16.1% of total net
revenue, compared to $0.1 million in the first quarter of 2019 and
($5.6) million in the second quarter of 2018.
Non-GAAP Net Income.
Non-GAAP net income for the quarter was $4.4 million and reflects
GAAP net loss excluding the non-recurring costs of the debt
refinancing, stock-based compensation and non-cash amortization of
intangible assets and warrant discounts.
Cash Position. BDSI had
cash and cash equivalents of approximately $57.2 million as of June
30, 2019. Based on current guidance, the company anticipates having
positive operating cash flow by the fourth quarter of 2019.
Conference Call & Webcast Details
BioDelivery Sciences will host a conference
call and webcast today, August 8, 2019, at 4:30 p.m.
ET to present second quarter 2019 results and to provide a
business update. Dial-in details are as follows:
Date: |
Thursday, August 8, 2019 |
Time: |
4:30 PM EDT |
Domestic: |
800-347-6311 |
International: |
720-543-0197 |
Passcode: |
868 4665 |
Webcast: |
http://public.viavid.com/index.php?id=135544 |
ABOUT BIODELIVERY SCIENCES INTERNATIONAL,
INC.
BioDelivery Sciences International,
Inc. (NASDAQ: BDSI) is a commercial-stage specialty
pharmaceutical company dedicated to patients living with chronic
conditions. BDSI has built a portfolio of products that includes
utilizing its novel and proprietary BioErodible MucoAdhesive
(BEMA®) technology to develop and commercialize, either on its own
or in partnership with third parties, new applications of proven
therapies aimed at addressing important unmet medical needs. BDSI's
marketed products and those in development address serious and
debilitating conditions such as chronic pain, breakthrough cancer
pain, opioid dependence, and opioid-induced constipation.
CAUTIONARY NOTE ON FORWARD-LOOKING
STATEMENTS
This press release and any statements of
employees, representatives, and partners of BioDelivery
Sciences International, Inc. (“BDSI”) related thereto contain,
or may contain, among other things, certain “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve
significant risks and uncertainties. Such statements may include,
without limitation, statements with respect to the BDSI’s plans,
objectives, projections, expectations and intentions and other
statements identified by words such as “projects,” “may,” “will,”
“could,” “would,” “should,” “believes,” “expects,” “anticipates,”
“estimates,” “intends,” “plans,” “potential” or similar
expressions. These statements are based upon the current beliefs
and expectations of the BDSI’s management and are subject to
significant risks and uncertainties, including those detailed in
the BDSI’s filings with the Securities and Exchange
Commission. Actual results (including, without limitation, the
continued growth in BELBUCA net revenues and total net revenues in
2019 and the implementation and success of our Symproic strategic
plan) may differ materially from those set forth or implied in the
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change
based on various factors (many of which are beyond the BDSI’s
control) including those set forth in our 2019 annual report on
Form 10-K filed with the US Securities and Exchange
Commission and subsequent filings. BDSI undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
© 2019 BioDelivery Sciences International,
Inc. All rights reserved.
Contact:
Mary ColemanVice President, Investor Relations and Corporate
CommunicationsBioDelivery Sciences International,
Inc.mcoleman@bdsi.com
|
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND
SUBSIDIARIES |
|
|
CONDENSED CONSOLIDATED BALANCE
SHEETS |
|
|
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE
AMOUNTS) |
|
|
(Unaudited) |
|
|
|
June 30, |
December 31, |
|
|
|
|
2019 |
|
|
2018 |
|
|
|
ASSETS |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash
equivalents |
$ |
57,215 |
|
$ |
43,822 |
|
|
|
Accounts receivable,
net. |
|
24,879 |
|
|
13,627 |
|
|
|
Inventory, net |
|
9,974 |
|
|
5,406 |
|
|
|
Prepaid expenses and other
current assets |
|
3,298 |
|
|
3,188 |
|
|
|
Total current assets |
|
95,366 |
|
|
66,043 |
|
|
|
|
|
|
|
|
Property and equipment, net |
|
3,853 |
|
|
3,072 |
|
|
|
Goodwill |
|
2,715 |
|
|
2,715 |
|
|
|
License and distribution rights,
net |
|
63,778 |
|
|
36,000 |
|
|
|
Other intangible assets, net |
|
375 |
|
|
703 |
|
|
|
Total assets |
$ |
166,087 |
|
$ |
108,533 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable and
accrued liabilities |
$ |
40,762 |
|
$ |
21,539 |
|
|
|
Total current
liabilities |
|
40,762 |
|
|
21,539 |
|
|
|
|
|
|
|
|
Notes payable, net |
|
58,448 |
|
|
51,652 |
|
|
|
Other long-term liabilities |
|
727 |
|
|
5,600 |
|
|
|
Total liabilities |
|
99,937 |
|
|
78,791 |
|
|
|
|
|
|
|
|
Commitments and
contingencies |
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
Preferred Stock, 5,000,000 shares
authorized; Series A Non-Voting Convertible Preferred Stock. $.001
par value, 2,093,155 shares outstanding at both June 30, 2019 and
December 31, 2018, respectively; Series B Non-Voting Convertible
Preferred Stock, $.001 par value, 1,716 and 3,100 shares
outstanding at June 30, 2019 and December 31, 2018,
respectively. |
|
2 |
|
|
2 |
|
|
|
Common Stock, $.001 par value;
125,000,000 shares authorized at June 30, 2019 and
December 31, 2018, respectively; 89,535,024 and 75,793,725
shares issued;89,519,533 and 70,778,234 shares outstanding at June
30, 2019 and December 31, 2018, respectively. |
|
88 |
|
|
71 |
|
|
|
Additional paid-in capital |
|
432,358 |
|
|
381,004 |
|
|
|
Treasury stock, at cost, 15,491
shares |
|
(47 |
) |
|
(47 |
) |
|
|
Accumulated deficit |
|
(366,251 |
) |
|
(351,288 |
) |
|
|
Total stockholders'
equity |
|
66,150 |
|
|
29,742 |
|
|
|
|
|
|
|
|
Total liabilities and
stockholders' equity |
$ |
166,087 |
|
$ |
108,533 |
|
|
|
|
|
|
|
|
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND
SUBSIDIARIES |
|
|
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
|
|
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE
AMOUNTS) |
|
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
|
|
2019 |
|
|
2018 |
|
|
|
2019 |
|
|
2018 |
|
|
|
Revenues: |
|
|
|
|
|
|
|
Product sales |
$ |
28,056 |
|
$ |
10,766 |
|
|
$ |
47,815 |
|
$ |
20,604 |
|
|
|
Product royalty
revenues |
|
1,461 |
|
|
1,386 |
|
|
|
1,471 |
|
|
1,826 |
|
|
|
Contract revenue |
|
160 |
|
|
23 |
|
|
|
160 |
|
|
1,026 |
|
|
|
Total Revenues: |
|
29,677 |
|
|
12,175 |
|
|
|
49,446 |
|
|
23,456 |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
4,923 |
|
|
4,566 |
|
|
|
8,975 |
|
|
7,981 |
|
|
|
|
|
|
|
|
|
|
|
Expenses: |
|
|
|
|
|
|
|
Research and
development: |
|
- |
|
|
854 |
|
|
|
- |
|
|
3,338 |
|
|
|
Sales, general and
administrative |
|
21,955 |
|
|
14,021 |
|
|
|
38,944 |
|
|
27,526 |
|
|
|
Total Expenses: |
|
21,955 |
|
|
14,875 |
|
|
|
38,944 |
|
|
30,864 |
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from
operations |
|
2,799 |
|
|
(7,266 |
) |
|
|
1,527 |
|
|
(15,389 |
) |
|
|
Interest expense |
|
(13,937 |
) |
|
(2,525 |
) |
|
|
(16,498 |
) |
|
(5,030 |
) |
|
|
Other (expense) income, net |
|
8 |
|
|
1 |
|
|
|
8 |
|
|
(6 |
) |
|
|
Loss before income taxes |
$ |
(11,130 |
) |
$ |
(9,790 |
) |
|
$ |
(14,963 |
) |
$ |
(20,425 |
) |
|
|
|
|
|
|
|
|
|
|
Income tax benefit (expense) |
|
- |
|
|
20 |
|
|
|
- |
|
|
(54 |
) |
|
|
Net loss attributable to common
stockholders |
$ |
(11,130 |
) |
$ |
(9,770 |
) |
|
$ |
(14,963 |
) |
$ |
(20,479 |
) |
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
|
|
|
|
|
Weighted average common stock
shares outstanding: |
|
83,821,811 |
|
|
59,400,317 |
|
|
|
77,571,003 |
|
|
58,735,351 |
|
|
|
Basic and diluted loss per
share: |
$ |
(0.13 |
) |
$ |
(0.16 |
) |
|
$ |
(0.19 |
) |
$ |
(0.35 |
) |
|
|
|
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND
SUBSIDIARIES |
|
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS |
|
|
(U.S. DOLLARS, IN
THOUSANDS) |
|
|
(Unaudited) |
|
|
|
|
Six Months Ended June
30, |
|
|
|
|
|
2018 |
|
|
2018 |
|
|
Operating
activities: |
|
|
|
|
Net loss |
|
$ |
(14,963 |
) |
$ |
(20,479 |
) |
|
|
|
Depreciation and
amortization |
|
168 |
|
|
456 |
|
|
|
|
Impairment loss on equipment |
|
- |
|
|
78 |
|
|
|
|
Accretion of debt discount and
loan costs |
|
11,374 |
|
|
1,782 |
|
|
|
|
Amortization of intangible
assets |
|
3,187 |
|
|
2,578 |
|
|
|
|
Provision for inventory
obsolescence |
|
149 |
|
|
412 |
|
|
|
|
Stock-based compensation
expense |
|
2,711 |
|
|
4,004 |
|
|
|
Changes in assets and
liabilities, net of effect of acquisition: |
|
|
|
|
|
Accounts receivable |
|
(11,252 |
) |
|
(423 |
) |
|
|
|
Inventories |
|
(4,716 |
) |
|
(489 |
) |
|
|
|
Prepaid expenses and other
assets |
|
(110 |
) |
|
1,454 |
|
|
|
|
Accounts payable and accrued
expenses |
|
9,078 |
|
|
(1,118 |
) |
|
|
Net cash flows from
operating activities |
|
(4,374 |
) |
|
(11,745 |
) |
|
|
|
|
|
|
|
Investing
activities: |
|
|
|
|
|
Product acquisitions |
|
(20,674 |
) |
|
(1,951 |
) |
|
|
|
Acquisitions of equipment |
|
(79 |
) |
|
(122 |
) |
|
|
Net cash flows from
investing activities |
|
(20,753 |
) |
|
(2,073 |
) |
|
|
|
|
|
|
|
Financing
activities: |
|
|
|
|
|
Proceeds from issuance of common
stock |
|
48,000 |
|
|
- |
|
|
|
|
Proceeds from issuance of Series
B preferred stock |
|
- |
|
|
50,000 |
|
|
|
|
Equity financing costs |
|
(410 |
) |
|
(1,509 |
) |
|
|
|
Proceeds from notes payable |
|
60,000 |
|
|
- |
|
|
|
|
Proceeds from exercise of stock
options |
|
1,070 |
|
|
306 |
|
|
|
|
Payment of notes payable |
|
(67,346 |
) |
|
- |
|
|
|
|
Loss on refinancing of former
debt |
|
(2,794 |
) |
|
- |
|
|
|
|
Payment of deferred financing
fees |
|
- |
|
|
(450 |
) |
|
|
Net cash flows from
financing activities |
|
38,520 |
|
|
48,347 |
|
|
Net change in cash
and cash equivalents |
|
13,393 |
|
|
34,529 |
|
|
Cash and cash
equivalents at beginning of year |
|
43,822 |
|
|
21,195 |
|
|
Cash and cash
equivalents at end of year |
$ |
57,215 |
|
$ |
55,724 |
|
|
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND
SUBSIDIARIES |
|
|
RECONCILIATION OF NON-GAAP METRICS |
|
|
(U.S. DOLLARS, IN
THOUSANDS) |
|
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of GAAP net income/(loss) to EBITDA
(non-GAAP) |
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
|
|
|
2019 |
|
|
2018 |
|
|
|
2019 |
|
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net
income/(loss) |
|
$ |
(11,130 |
) |
$ |
(9,770 |
) |
|
$ |
(14,963 |
) |
$ |
(20,479 |
) |
|
|
Add back: |
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
- |
|
|
(20 |
) |
|
|
- |
|
|
53 |
|
|
|
Net interest expense |
|
|
13,929 |
|
|
2,525 |
|
|
|
16,490 |
|
|
5,037 |
|
|
|
Depreciation and amortization |
|
|
1,981 |
|
|
1,679 |
|
|
|
3,356 |
|
|
3,199 |
|
|
|
EBITDA |
|
$ |
4,780 |
|
$ |
(5,586 |
) |
|
$ |
4,883 |
|
$ |
(12,190 |
) |
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of GAAP net income/(loss) to non-GAAP net
income/(loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net
income/(loss) |
|
$ |
(11,130 |
) |
$ |
(9,770 |
) |
|
$ |
(14,963 |
) |
$ |
(20,479 |
) |
|
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
1,569 |
|
|
1,084 |
|
|
|
2,712 |
|
|
4,005 |
|
|
|
Amortization of intangible assets |
|
|
1,898 |
|
|
1,289 |
|
|
|
3,187 |
|
|
2,578 |
|
|
|
Amortization of warrant discount |
|
|
179 |
|
|
269 |
|
|
|
448 |
|
|
538 |
|
|
|
Non-recurring financial impact of debt refinance |
|
11,866 |
|
|
- |
|
|
|
11,866 |
|
|
- |
|
|
|
Non-GAAP net income/(loss) |
|
$ |
4,382 |
|
$ |
(7,128 |
) |
|
$ |
3,250 |
|
$ |
(13,358 |
) |
|
|
|
|
|
|
|
|
|
|
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Apr 2023 to Apr 2024